Dr Scott J Turner | Specialist Plastic Surgeon (FRACS) | Sydney
Few topics in modern breast surgery have drifted as far between marketing language and clinical evidence as en-bloc capsulectomy. Walk through enough clinic websites and you’ll see “true en-bloc” promoted as a specific technique, sometimes positioned as the only way to address breast implant illness symptoms. The clinical reality is more nuanced. The evidence doesn’t establish en-bloc as superior to partial capsulectomy for symptom improvement, the term itself has been adopted from oncology in ways that aren’t always accurate, and what’s actually achieved during surgery varies considerably between providers regardless of what’s labelled in the booking.
This guide is for women considering breast implant removal who want a straight account of what the clinical and research consensus actually says. It covers the en-bloc terminology debate, the evidence on symptom improvement after explant, and what to look for and what to be wary of when evaluating clinics. I’m Dr Scott J Turner, a Specialist Plastic Surgeon (FRACS) at our Bondi Junction and Manly clinics. For the practical recovery side of explant, see recovery after breast implant removal. For the symptom-and-evidence side, see breast implant illness.
Definitions: What Each Term Actually Means
A lot of the confusion around explant comes from terminology used loosely. A quick clarifier on what each term means in surgical practice:
- Implant removal alone: the implants are removed through the original incision, the pocket is cleaned, and the surrounding capsule is left in place to gradually reabsorb over time.
- Partial capsulectomy: the implants are removed plus a portion of the surrounding capsule. Capsule tissue that’s adherent to underlying structures or that doesn’t show signs of pathology is left in place.
- Total capsulectomy: the entire capsule is removed, but not necessarily as a single intact specimen.
- Intact capsulectomy: the entire capsule is removed in one piece, with the implant still inside.
- En-bloc resection: an oncology term for removing a tumour along with surrounding tissue as a single intact specimen. Used appropriately in cancer surgery. Often misapplied in BII marketing to mean intact capsulectomy.
These distinctions matter because patients, surgeons, and oncologists often use the same words to mean different things, and clinics sometimes use the most clinical-sounding term in marketing regardless of what’s actually performed.
The Symptoms That Drive the Conversation
Some women with breast implants experience a constellation of systemic symptoms that they attribute to the implants. The most common term for this is Breast Implant Illness (BII). Some clinical bodies have proposed Systemic Symptoms Associated with Breast Implants (SSBI) as a more neutral alternative because it doesn’t imply a causation that hasn’t been definitively proven.
The symptom list is broad. Over 100 different symptoms have been reported in the literature, and there’s no specific pattern that defines a single diagnostic test. The most commonly reported include fatigue, brain fog, joint and muscle pain, skin changes, and a generalised sense of being unwell. The Therapeutic Goods Administration (TGA) in Australia and the FDA in the United States now both include patient information and warnings regarding systemic symptoms in their materials about breast implants.
What the Evidence Currently Supports
The evidence on BII and explant has developed considerably over the past several years. The areas of reasonable agreement relate to reported symptoms and outcomes after implant removal, rather than to a unified causal mechanism. The current state of evidence supports the following:
- Patients have reported these symptoms with implants of all types, including saline and silicone gel, smooth and textured surfaces, and across all manufacturers. There is no single implant brand or type that accounts for the syndrome.
- Some patients experience meaningful symptom improvement after implant removal. The proportion who improve, the degree of improvement, and the timing all vary substantially between patients.
- Studies funded by the Aesthetic Surgery Education and Research Foundation (ASERF) comparing women with self-described BII to control groups have shown the BII group had more symptoms at baseline and experienced rapid symptom improvement after implant removal. The studies did not find significant differences in biospecimens between the BII group and control groups.
- The evidence does not establish that any specific surgical technique (en-bloc capsulectomy versus partial capsulectomy versus implant removal alone) produces meaningfully better symptom improvement for BII.
The mechanism by which symptoms improve isn’t fully understood, and the cause of the symptoms in the first place isn’t definitively established. Improvement after explant is real and clinically meaningful, but doesn’t by itself prove the implants were the sole cause.
The En-Bloc Terminology Debate
The term “en-bloc” originates from oncology, where it describes removing a tumour with surrounding tissue as a single intact specimen to prevent tumour cell spread. It has a specific clinical purpose in cancer surgery. Patients often use the term to mean intact capsule removal, surgeons sometimes use it loosely for total capsulectomy of any kind, and some clinics use it as a marketing claim that implies a clinical necessity not supported by the evidence.
That said, en-bloc as a patient preference is a separate matter from en-bloc as a marketing claim. Some patients genuinely prefer en-bloc capsulectomy, particularly with BII concerns or known silicone implant rupture where they want maximum reassurance about silicone containment. This is a reasonable personal preference. Where en-bloc is the surgical plan, every effort is made to remove the entire capsule. The honest qualification: complete intact removal isn’t always anatomically achievable. The capsule can be adherent to underlying structures including the ribs, the chest muscle, and the lung lining, and forcing complete removal in those areas can create unnecessary risk. Patient safety takes priority over technique purity.
For most BII explant cases, partial capsulectomy is clinically sufficient, and the evidence doesn’t establish en-bloc as superior for symptom improvement. The choice between approaches should be individualised based on capsule thickness, implant integrity, patient preference, and the technical feasibility of complete removal in your specific anatomy.
When Different Surgical Approaches May Be Appropriate
The right surgical approach depends on the indication for surgery, what’s found at imaging, and what’s safe to attempt during the procedure. As a general guide:
- Implant removal alone can be appropriate for patients with intact implants, no significant capsular contracture, and no other capsular pathology. The capsule gradually reabsorbs over time.
- Partial capsulectomy is the most commonly used approach across BII concerns, mild capsular contracture, and routine explant. It removes the capsule where pathology exists or where complete removal is straightforward, and leaves capsule that’s adherent to underlying structures.
- Total capsulectomy may be considered for significant capsular contracture, calcification, or thickening of the capsule that the patient or surgeon wants fully removed.
- Intact capsulectomy is sometimes attempted by patient preference or where confirmed silicone rupture means keeping the capsule intact reduces silicone spread during removal.
- True oncologic en-bloc resection is reserved for confirmed or suspected malignancy such as BIA-ALCL, where intact removal of the surrounding tissue is part of the cancer treatment.
The decision in any individual case takes into account symptoms, imaging findings, intraoperative findings, and what’s safe to attempt. A surgeon who can articulate why a specific approach suits your specific case is giving you better information than one who applies a single technique to every patient.
Choosing a Surgeon for Breast Implant Removal
The relevant qualifications for explant surgery in Australia are the same as for any breast surgery: Fellowship of the Royal Australasian College of Surgeons (FRACS) in Plastic Surgery, current AHPRA registration as a Specialist Plastic Surgeon, hospital admitting rights at accredited facilities, and active membership in professional societies including the Australian Society of Plastic Surgeons (ASPS). Surgical experience with breast implant removal is reasonable to ask about. There is no recognised “explant expert” sub-specialty designation in Australia.
When evaluating a clinic, look for:
- Verifiable credentials and AHPRA registration
- Hospital admitting rights at accredited private hospitals (rather than day-only facilities)
- A consultation that involves measurement, examination, imaging review, and a discussion of multiple surgical options
- Honest framing of the evidence on outcomes, including the parts where evidence is uncertain
- Willingness to recommend medical workup before surgery rather than fast-tracking to operation
Be cautious of marketing that:
- Promotes a specific surgical technique as the only or best approach without qualification
- Uses oncology terminology like “en-bloc” prominently in marketing without acknowledging its specific clinical meaning
- Promises symptom resolution after explant
- Positions BII as a clearly defined diagnosis with established diagnostic criteria
- Discourages standard medical workup before surgery
- Pressures quick decision-making without time for reflection
These are evidence and consent considerations rather than personal criticisms of any individual provider. The intent is to give patients a framework for assessing claims rather than relying on marketing language alone.
What a Properly Conducted Explant Pathway Looks Like
Before surgery is considered, good practice typically includes a medical workup to rule out alternative causes for systemic symptoms. This may involve blood tests for inflammatory markers, thyroid function, hormonal status, vitamin levels, and screening for autoimmune conditions. For some patients, assessment by a rheumatologist, endocrinologist, or other specialist is appropriate before considering explant. Many patients who present with concerns about BII have a different underlying cause for their symptoms that responds to other treatment.
Imaging is appropriate where complications are suspected. MRI is the most reliable test for detecting silent rupture in silicone gel implants. Ultrasound can identify capsular issues and seromas. Mammogram screening should continue at the recommended interval.
The preoperative pathway in Australia should include appropriate medical assessment, careful informed consent, and compliance with current regulatory requirements for cosmetic surgery where applicable. Depending on the indication for surgery, this may include GP involvement, psychological screening, two-consultation frameworks, and cooling-off periods. Cosmetic explant for purely personal reasons follows the cosmetic surgery requirements introduced in July 2023. Explant for clearly medical indications such as confirmed rupture or capsular contracture follows a more standard surgical consultation pathway. Your surgeon will explain which framework applies to your specific situation.
The surgical conversation should cover what’s actually planned. If a partial capsulectomy is appropriate, this should be explained as the recommended approach for your situation rather than positioned as a lesser version of “en bloc.” If en-bloc is being attempted, the patient should understand that complete intact capsule removal isn’t always achievable and that anatomical and safety limitations may prevent it.
What Honest Pre-Surgery Counselling Includes
A clinic that promises symptom resolution after explant is overstating what the evidence supports. The honest pre-surgery conversation should include realistic outcome expectations: meaningful improvement is the most likely scenario, but it isn’t universal, and the timing varies. Some patients see significant improvement within weeks. Others see partial improvement that builds over months. A smaller proportion don’t see meaningful change.
The mechanism for symptom improvement isn’t fully understood. Whether it’s resolution of an immune response to the implant, removal of low-grade biofilm contamination, placebo effect, or some combination is genuinely uncertain. What’s clear is that symptom improvement after explant is a real and clinically meaningful outcome, even without complete mechanistic understanding.
Australian Regulatory Context
The TGA has cancelled the registration of specific breast implant products where significant risk has been identified. Macrotextured implants linked to BIA-ALCL (a rare cancer) have been largely withdrawn from the Australian market. The Australian Breast Device Registry (ABDR) tracks breast implant surgeries, complications, and outcomes nationally, providing the data infrastructure for identifying patterns of implant-related issues over time.
If you’ve had implant surgery in Australia in recent years, your surgical data may be in the ABDR. If you’re considering explant and want your case to contribute to the evolving evidence base, ask your surgeon whether your procedure will be entered into the registry.
What This Means for You as a Patient
If you’re considering breast implant removal, the practical takeaways from this advisory:
Don’t choose a surgeon based on marketing language about specific techniques. Choose based on credentials, hospital privileges, and the quality of the consultation conversation.
Be wary of clinics that promise specific outcomes or position one surgical technique as universally superior. The evidence doesn’t support these claims for BII.
Get a thorough medical workup before assuming your symptoms are caused by your implants. Many alternative explanations are treatable, and identifying or ruling them out before surgery is part of good clinical practice.
Have a frank conversation about expected outcomes. A surgeon who acknowledges the uncertainty about explant outcomes and presents the honest range of possibilities is giving you better information than one who promises certain symptom resolution.
The evidence on BII and explant continues to develop. What we know in 2026 is more than we knew five years ago, and what we know in 2030 will be more again. Recommendations may evolve as more data becomes available.
Book a Consultation
If you’re considering breast implant removal and want a careful, evidence-based opinion on whether implant removal alone, partial capsulectomy, or total capsulectomy is appropriate in your case, you can book a consultation with Dr Scott J Turner at our Bondi Junction or Manly clinics. Dr Turner also consults at Brisbane, Canberra, and Newcastle.
For explant being considered for medical reasons including BII concerns, capsular contracture, or rupture, a GP referral is recommended because it carries forward your medical history and any workup that’s been done. Your surgeon will explain which consultation framework applies to your specific case based on the indication for surgery.
Contact our clinic or call 1300 437 758.
